Bank of America Securities analyst Travis Steed maintained a Sell rating on Embecta Corporation (EMBC – Research Report) today. The company’s shares opened today at $14.44.
According to TipRanks, Steed is a 4-star analyst with an average return of 6.7% and a 64.43% success rate. Steed covers the Healthcare sector, focusing on stocks such as Stryker, Shockwave Medical, and Edwards Lifesciences.
The analyst consensus on Embecta Corporation is currently a Moderate Sell rating.
EMBC market cap is currently $821.2M and has a P/E ratio of 11.70.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Embecta Corporation (EMBC) Company Description:
Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.
